Published in Proc Natl Acad Sci U S A on October 31, 2008
Aptamers as therapeutics. Nat Rev Drug Discov (2010) 5.36
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) (2011) 3.62
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc (2009) 2.16
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
More effective nanomedicines through particle design. Small (2011) 1.80
Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging (2010) 1.75
"OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res (2012) 1.75
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med (2010) 1.71
Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One (2011) 1.58
Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids (2014) 1.49
Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc (2009) 1.43
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci U S A (2009) 1.43
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci (2012) 1.40
Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A (2010) 1.35
Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem (2012) 1.34
Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. Mol Ther Nucleic Acids (2014) 1.32
Protein-assisted self-assembly of multifunctional nanoparticles. Proc Natl Acad Sci U S A (2010) 1.30
Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A (2012) 1.27
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine (2011) 1.26
An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids (2012) 1.25
Porous hollow Fe(3)O(4) nanoparticles for targeted delivery and controlled release of cisplatin. J Am Chem Soc (2009) 1.25
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A (2010) 1.20
Aptamer-targeted cell-specific RNA interference. Silence (2010) 1.17
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther (2011) 1.16
Hybrid nanoparticles for detection and treatment of cancer. Adv Mater (2012) 1.16
Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev (2010) 1.14
Monofunctional and higher-valent platinum anticancer agents. Inorg Chem (2013) 1.13
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano (2010) 1.12
GCPII imaging and cancer. Curr Med Chem (2012) 1.12
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev (2013) 1.11
Inorganic nanoparticles in cancer therapy. Pharm Res (2010) 1.11
Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides (2010) 1.10
Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med (2012) 1.10
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials (2013) 1.07
Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chem Commun (Camb) (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev (2012) 1.06
Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One (2011) 1.05
Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J Pharm Sci (2010) 1.05
Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv (2010) 1.05
Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release. Angew Chem Int Ed Engl (2011) 1.04
Cell-specific aptamers as emerging therapeutics. J Nucleic Acids (2011) 1.04
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine (2011) 1.04
Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release (2011) 1.03
Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano (2013) 1.02
Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci Transl Med (2014) 1.01
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A (2015) 1.01
Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine (2015) 1.00
Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev (2011) 1.00
Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc Natl Acad Sci U S A (2014) 1.00
α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano (2012) 1.00
Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci (2012) 0.99
Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates. ACS Nano (2011) 0.99
Polymeric Nanostructures for Imaging and Therapy. Chem Rev (2015) 0.99
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond) (2012) 0.97
Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release (2013) 0.97
A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc (2014) 0.97
Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc (2014) 0.97
Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun (2015) 0.97
Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol (2014) 0.96
Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers. ACS Nano (2014) 0.95
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm (2009) 0.95
Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages. Mol Ther Nucleic Acids (2013) 0.94
Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery. Bioorg Med Chem Lett (2010) 0.94
Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc (2010) 0.94
Nanotechnology-based approaches in anticancer research. Int J Nanomedicine (2012) 0.93
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm (2012) 0.91
Tumor-targeted drug delivery with aptamers. Curr Med Chem (2011) 0.91
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One (2012) 0.89
Aptamer-Drug Conjugates. Bioconjug Chem (2015) 0.89
Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology (2011) 0.88
Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano (2013) 0.88
Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biol (2012) 0.87
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci U S A (2016) 0.87
Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics (2015) 0.87
Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem (2012) 0.87
Prodrug applications for targeted cancer therapy. AAPS J (2014) 0.87
Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles. ACS Chem Biol (2013) 0.87
Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (2011) 0.87
Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents. Organometallics (2012) 0.87
Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics (2014) 0.86
The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs. Inorg Chem (2013) 0.86
Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.85
SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors. Nanoscale (2011) 0.84
Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol Pharm (2013) 0.84
Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches. Adv Funct Mater (2016) 0.84
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano (2013) 0.84
Polydopamine-Based Surface Modification of Novel Nanoparticle-Aptamer Bioconjugates for In Vivo Breast Cancer Targeting and Enhanced Therapeutic Effects. Theranostics (2016) 0.84
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Drug delivery and targeting. Nature (1998) 6.16
Platinum compounds: a new class of potent antitumour agents. Nature (1969) 5.92
Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther (2007) 5.79
Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev (1999) 5.63
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 4.97
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 4.16
Small-scale systems for in vivo drug delivery. Nat Biotechnol (2003) 3.90
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc (2007) 2.82
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc (2008) 2.40
Drug delivery. Drugs on target. Science (2001) 2.39
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release (2002) 2.26
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci (2008) 2.21
MEROPS: the protease database. Nucleic Acids Res (2002) 2.21
Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc (2008) 1.97
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res (2006) 1.65
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (1998) 1.61
Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release (2002) 1.58
Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. Inorg Chem (1995) 1.50
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release (2000) 1.50
Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem (2007) 1.46
Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res (1997) 1.44
The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. J Biol Inorg Chem (2003) 1.25
Water soluble polymers in tumor targeted delivery. J Control Release (2001) 1.16
Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Control Release (1998) 1.10
Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J Control Release (2003) 1.08
Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm (2007) 1.08
Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target (2001) 1.07
In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules (2006) 1.04
Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm (2007) 0.90
The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med (2000) 0.84
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov (2005) 9.47
Engineering vascularized skeletal muscle tissue. Nat Biotechnol (2005) 7.73
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A (2006) 6.66
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells. Nat Biotechnol (2004) 5.51
Transdermal drug delivery. Nat Biotechnol (2008) 5.11
Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A (2002) 4.77
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res (2004) 4.56
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
A tough biodegradable elastomer. Nat Biotechnol (2002) 4.35
Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25
Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci U S A (2004) 4.13
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials (2006) 4.09
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med (2005) 4.04
Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater (2008) 4.00
A reversibly switching surface. Science (2003) 3.97
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Small-scale systems for in vivo drug delivery. Nat Biotechnol (2003) 3.90
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A (2008) 3.80
Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75
Synthetic models for non-heme carboxylate-bridged diiron metalloproteins: strategies and tactics. Chem Rev (2004) 3.73
Endothelial cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 3.66
First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med (2012) 3.56
Controlled degradation and mechanical behavior of photopolymerized hyaluronic acid networks. Biomacromolecules (2005) 3.44
Direct cellular responses to platinum-induced DNA damage. Chem Rev (2007) 3.42
Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov (2004) 3.41
Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci (2006) 3.35
Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A (2002) 3.35
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev (2012) 3.34
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells. Proc Natl Acad Sci U S A (2007) 3.19
Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med (2008) 3.16
Nanotechnological strategies for engineering complex tissues. Nat Nanotechnol (2010) 3.15
Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater (2010) 3.11
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Engineering substrate topography at the micro- and nanoscale to control cell function. Angew Chem Int Ed Engl (2009) 3.09
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Microengineered hydrogels for tissue engineering. Biomaterials (2007) 2.87
Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci U S A (2003) 2.86
Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew Chem Int Ed Engl (2003) 2.83
Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc (2007) 2.82
The inflammatory responses to silk films in vitro and in vivo. Biomaterials (2005) 2.79
Biodegradable, elastic shape-memory polymers for potential biomedical applications. Science (2002) 2.79
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev (2006) 2.69
Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater (2003) 2.65
A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res (2008) 2.63
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
A biodegradable and biocompatible gecko-inspired tissue adhesive. Proc Natl Acad Sci U S A (2008) 2.58
Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat Mater (2012) 2.57
Light-induced shape-memory polymers. Nature (2005) 2.52
Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation (2005) 2.49
Medium perfusion enables engineering of compact and contractile cardiac tissue. Am J Physiol Heart Circ Physiol (2003) 2.42
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc (2008) 2.40
A vector-free microfluidic platform for intracellular delivery. Proc Natl Acad Sci U S A (2013) 2.40
Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther (2009) 2.39
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl (2006) 2.38
Bio-inspired polymer composite actuator and generator driven by water gradients. Science (2013) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett (2010) 2.35
Visualization of nitric oxide in living cells by a copper-based fluorescent probe. Nat Chem Biol (2006) 2.33
Controlling size, shape and homogeneity of embryoid bodies using poly(ethylene glycol) microwells. Lab Chip (2007) 2.30
Biocompatibility and biofouling of MEMS drug delivery devices. Biomaterials (2003) 2.27
Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng (2004) 2.26
Endothelialized microvasculature based on a biodegradable elastomer. Tissue Eng (2005) 2.23
Silk implants for the healing of critical size bone defects. Bone (2005) 2.22
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials (2008) 2.21
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Biomimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. Tissue Eng (2006) 2.20
Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc (2009) 2.16
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
Micromolding of shape-controlled, harvestable cell-laden hydrogels. Biomaterials (2006) 2.12
Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed (2007) 2.12
Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ Res (2007) 2.12